Q1 Earnings Estimate for Exelixis Issued By William Blair

Exelixis, Inc. (NASDAQ:EXEL) – Investment analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for shares of Exelixis in a note issued to investors on Monday, April 28th. William Blair analyst A. Hsieh expects that the biotechnology company will post earnings of $0.44 per share for the quarter. The consensus estimate for Exelixis’ current full-year earnings is $2.04 per share. William Blair also issued estimates for Exelixis’ Q2 2026 earnings at $0.48 EPS, Q3 2026 earnings at $0.50 EPS and Q4 2026 earnings at $0.52 EPS.

Several other equities research analysts have also weighed in on the company. Wells Fargo & Company reissued a “market outperform” rating on shares of Exelixis in a research report on Thursday, April 17th. Piper Sandler raised their price objective on shares of Exelixis from $37.00 to $38.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Barclays upped their target price on shares of Exelixis from $25.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, February 13th. Truist Financial lifted their price target on shares of Exelixis from $42.00 to $43.00 and gave the stock a “buy” rating in a research note on Monday, January 27th. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Exelixis in a research note on Thursday, March 27th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Exelixis currently has an average rating of “Moderate Buy” and an average target price of $37.59.

Exelixis Price Performance

Exelixis stock opened at $38.89 on Thursday. The stock has a market cap of $10.72 billion, a PE ratio of 21.97, a P/E/G ratio of 1.13 and a beta of 0.57. The stock’s fifty day moving average is $36.90 and its two-hundred day moving average is $34.96. Exelixis has a 1-year low of $20.14 and a 1-year high of $40.02.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%.

Insider Buying and Selling

In other news, Director Jack L. Wyszomierski sold 8,768 shares of the firm’s stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $37.80, for a total value of $331,430.40. Following the completion of the sale, the director now directly owns 356,605 shares of the company’s stock, valued at $13,479,669. This trade represents a 2.40 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bob Oliver sold 18,647 shares of the company’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $37.25, for a total value of $694,600.75. Following the transaction, the director now directly owns 33,514 shares in the company, valued at $1,248,396.50. This represents a 35.75 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 140,343 shares of company stock valued at $5,177,234 over the last three months. 2.85% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Exelixis

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Invesco Ltd. increased its holdings in Exelixis by 308.1% in the fourth quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company’s stock valued at $132,376,000 after buying an additional 3,001,204 shares in the last quarter. Norges Bank purchased a new position in Exelixis in the 4th quarter valued at approximately $94,867,000. Caisse DE Depot ET Placement DU Quebec raised its holdings in Exelixis by 330.4% during the fourth quarter. Caisse DE Depot ET Placement DU Quebec now owns 2,484,395 shares of the biotechnology company’s stock worth $82,730,000 after purchasing an additional 1,907,167 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its position in Exelixis by 104.4% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 3,159,395 shares of the biotechnology company’s stock worth $105,208,000 after purchasing an additional 1,613,482 shares in the last quarter. Finally, Voloridge Investment Management LLC purchased a new stake in Exelixis during the fourth quarter worth $30,321,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.